A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma.

Trial Profile

A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Irinotecan (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Doxorubicin; Mesna; Pegfilgrastim; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jan 2014 Status changed from recruiting to active, no longer recruiting.
    • 09 Jul 2012 Planned end date changed from 1 Jun 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top